A Double-blind, Placebo-Controlled, Fixed-Dose Study of Levomilnacipran SR in Patients With Major Depressive Disorder

Trial Profile

A Double-blind, Placebo-Controlled, Fixed-Dose Study of Levomilnacipran SR in Patients With Major Depressive Disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2015

At a glance

  • Drugs Levomilnacipran (Primary)
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 20 May 2015 Pooled analysis (recurrent and first episode MDD) results presented at the 168th Annual Meeting of the American Psychiatric Association.
    • 20 May 2015 Pooled analysis (noradrenergic symptoms, anxiety and functional impairment in adults) results presented at the 168th Annual Meeting of the American Psychiatric Association.
    • 09 Oct 2013 Pooled results for patient subgroups from 5 trials presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top